Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VR776
- Development stage
- Phase 2
- Lead developer
- Phillips-Medisize
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
VR776 is a proprietary, inhaled formulation of an undisclosed centrally-acting drug developed by Vectura for the treatment of premature ejaculation. The product utilizes Vectura's Aspirair dry powder inhaler (DPI) and PowderHale technology to ensure efficient delivery and rapid systemic absorption through the lungs. Designed to work within the central nervous system to delay ejaculation, VR776 has demonstrated a rapid onset of action (within 15 minutes) and improved intravaginal ejaculatory latency time (IVELT) in Phase IIa clinical trials. It represents a novel approach to premature ejaculation therapy, offering a faster-acting alternative to conventional oral medications.
Beyond the preview
Go deeper on VR776.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VR776.